Innovative combination Finasteride + Tadalafil

Products

Information

Innovative combination Finasteride + Tadalafil Both products individually are approved for BPH (Benign prostatic hyperplasia) in Europe. The most frequent adverse reactions are impotence and decreased libido in Finasteride. The benefit of Tadalafil is early onset of therapeutic effect and reduction of finasteride-induced adverse events (e.g. erectile dysfunction) Co-administration of Tadalafil 5 mg and finasteride 5 mg is recommended by European association of Urology (EAU - Guideline for Management of Non-neurogenic Male LUTS) and approved by FDA for BPH for up to 26 weeks For more details contact Vaibhav Sharma, Head of Value added products (Vaibhav.Sharma@zentiva.com )
All Categories
Tablets
Main Categories
Finished Dosage Forms (Products)
Distribution Areas
AfricaEast Asia (e.g. China, Japan, Korea)Europe - EU countriesEurope - non EU (e.g. UK, Russia, ex-CIS countries)South Asia (e.g. India, Pakistan, Sri Lanka)South East Asia (e.g. Thailand, Philippines, Singapore)
Zentiva Group, a.s.Zentiva provides health and wellbeing for all generations, with focus on developing, producing, and delivering high-quality, affordable medicines to more than 100 million people in over 30 countries across Europe and beyond. Zentiva has four wholly-owned manufacturing sites and a broad network of external manufacturing partners to ensure supply security. Zentiva employes more than 5,000 unique talents, bonded together by a commitment to the people who depend on our medicines every day. Zentiva is private equity-owned, delivering sustainable growth, with an ambitious plan for the years to come.

Log in

See all the content and easy-to-use features by logging in or registering!